Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and Fatty Liver, Nonalcoholic

olmesartan has been researched along with Fatty Liver, Nonalcoholic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dolci, M; Guaraldi, G; Lonardo, A; Mascia, MT; Nascimbeni, F; Reggiani Bonetti, L; Romagnoli, D1
Ioshii, SO; Précoma, DB; Sturzeneker, MC; Villela Baroncini, LA1

Other Studies

2 other study(ies) available for olmesartan and Fatty Liver, Nonalcoholic

ArticleYear
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:11

    Topics: Aged; Celiac Disease; Duodenum; Humans; Hypertension; Imidazoles; Liver; Male; Non-alcoholic Fatty Liver Disease; Tetrazoles

2016
Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.
    Atherosclerosis, 2011, Volume: 216, Issue:1

    Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol, Dietary; Disease Models, Animal; Fatty Liver; Hepatitis; Hypercholesterolemia; Imidazoles; Lipids; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Rabbits; Tetrazoles; Time Factors

2011